Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy

Journal of Clinical Oncology

Volumn 30, Issue 10, 2012, Pages 1080-1086

  Koppelmans, Vincent ^a,b   Breteler, Monique M B ^a,c,d   Boogerd, Willem ^b   Seynaeve, Caroline ^a   Gundy, Chad ^b   Schagen, Sanne B ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVOR; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EXPOSURE; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENTAL FUNCTION; MULTIPLE CYCLE TREATMENT; NEUROPSYCHOLOGY; PRIORITY JOURNAL; TASK PERFORMANCE; VERBAL MEMORY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COHORT STUDIES; CYCLOPHOSPHAMIDE; EXECUTIVE FUNCTION; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; SURVIVORS; TIME FACTORS;

EID: 84863752197     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.0189     Document Type: Article

References (78)

1. Abraham J, Haut MW, Moran MT, et al: Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 8:88-91, 2008 (Pubitemid 351346234)
2. Ahles TA, Saykin AJ, Furstenberg CT, et al: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493, 2002 (Pubitemid 34072533)
3. Ahles TA, Saykin AJ, McDonald BC, et al: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434-4440, 2010
4. Castellon SA, Silverman DH, Ganz PA: Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 92:199-206, 2005 (Pubitemid 41279630)
5. de Ruiter MB, Reneman L, Boogerd W, et al: Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain Mapping 32:1206-1219, 2011
6. Debess J, Riis JØ, Engebjerg MC, et al: Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 121:91-100, 2010
7. Deprez S, Amant F, Yigit R, et al: Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 32:480-493, 2011
8. Hermelink K, Untch M, Lux MP, et al: Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905-1913, 2007 (Pubitemid 46668557)
9. Jansen CE, Cooper BA, Dodd MJ, et al: A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647-1656, 2011
10. Jansen CE, Dodd MJ, Miaskowski CA, et al: Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology 17:1189-1195, 2008
11. Jim HS, Donovan KA, Small BJ, et al: Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115:1776-1783, 2009
12. Reid-Arndt SA, Hsieh C, Perry MC: Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology 19:535-544, 2010
13. Schagen SB, Muller MJ, Boogerd W, et al: Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98:1742-1745, 2006 (Pubitemid 44942713)
14. Scherwath A, Mehnert A, Schleimer B, et al: Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 17:415-423, 2006 (Pubitemid 43329577)
15. Tager FA, McKinley PS, Schnabel FR, et al: The cognitive effects of chemotherapy in postmenopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 123:25-34, 2010
16. van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218, 1998 (Pubitemid 28114539)
17. Vearncombe KJ, Rolfe M, Wright M, et al: Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15:951-962, 2009
18. Wefel JS, Saleeba AK, Buzdar AU, et al: Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348-3356, 2010
19. Weis J, Poppelreuter M, Bartsch HH: Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psychooncology 18:775-782, 2009
20. Yamada TH, Denburg NL, Beglinger LJ, et al: Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 22:48-54, 2010
21. Wefel JS, Vardy J, Ahles T, et al: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703-708, 2011
22. Castellon SA, Ganz PA, Bower JE, et al: Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955-969, 2004 (Pubitemid 39577316)
23. Ahles TA, Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7:192-201, 2007
24. de Ruiter MB, Reneman L, Boogerd W, et al: Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Human Brain Mapping [epub ahead of print on September 23, 2011]
25. Deprez S, Amant F, Smeets A, et al: Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30:274-281, 2011
26. Ferguson RJ, McDonald BC, Saykin AJ, et al: Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 25:3866-3870, 2007 (Pubitemid 47477262)
27. Inagaki M, Yoshikawa E, Matsuoka Y, et al: Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109:146-156, 2007 (Pubitemid 46120202)
28. McDonald BC, Conroy SK, Ahles TA, et al: Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123:819-828, 2010
29. Saykin AJ, Ahles TA, McDonald BC: Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8:201-216, 2003 (Pubitemid 37474731)
30. Stemmer SM, Stears JC, Burton BS, et al: White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. AJNR Am J Neuroradiol 15:1267-1273, 1994 (Pubitemid 24257853)
31. Saykin AJ: Altered brain activation following systemic chemotherapy for breast cancer: Interim analysis from a prospective study. J Int Neuropsychol Soc 12:131, 2006
32. Seigers R, Fardell JE: Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. Neurosci Biobehav Rev 35:729-741, 2011
33. Hofman A, Breteler MM, van Duijn CM, et al: The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 24:553-572, 2009
34. Euser SM, Schram MT, Hofman A, et al: Measuring cognitive function with age: The influence of selection by health and survival. Epidemiology 19:440-447, 2008 (Pubitemid 351543522)
35. Tiffin J, Asher EJ: The Purdue pegboard; norms and studies of reliability and validity. J Appl Psychol 32:234-247, 1948
36. Folstein MF, Folstein SE, McHugh PR: "Minimental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975
37. Kalverboer AF, Deelman BG: De 15- woordentest A en B. Groningen, the Netherlands, Academisch Ziekenhuis, 1986
38. Tombaugh TN, McIntyre NJ: The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922-935, 1992
39. Houx PJ, Jolles J, Vreeling FW: Stroop interference: Aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 19:209-224, 1993 (Pubitemid 23308505)
40. Killgore WD, Glahn DC, Casasanto DJ: Development and validation of the Design Organization Test (DOT): A rapid screening instrument for assessing visuospatial ability. J Clin Exp Neuropsychol 27:449-459, 2005 (Pubitemid 40524507)
41. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, et al: Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 12:80-89, 2006 (Pubitemid 43379954)
42. van der Elst W, van Boxtel MP, van Breukelen GJ, et al: The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): Influence of age, education, and sex. J Clin Exp Neuropsychol 28:998-1009, 2006
43. Knight RG, Williams S, McGee R, et al: Psychometric properties of the Centre for Epidemiologic Studies Depression Scale (CES-D) in a sample of women in middle life. Behav Res Ther 35:373-380, 1997 (Pubitemid 27139912)
44. Radloff LS: The CES-D scale: A self-report depression scale for research in the genetal population. Appl Psychological Measurement 1:385-401, 1977
45. Dietrich J, Monje M, Wefel J, et al: Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13:1285-1295, 2008
46. Mahalanobis PC: On the generalised distance in statistics. Proceedings of the National Institute of Sciences of India 2:49-55, 1936. http://www. new.dli.ernet.in/rawdataupload/upload/insa/INSA-1/ 20006193-49.pdf
47. Tabachnick BG, Fidell LS: Using Multivariate Statistics (ed 4). Needham Heights, MA, Allyn & Bacon, 2001, pp 68
48. DeCarlo LT: On the meaning and use of kurtosis. Psychol Met 2:292-307, 1997
49. Follmann D: A simple multivariate test for one-sided alternatives. J Am Stat Assoc 91:854-861, 1996
50. Wefel JS, Lenzi R, Theriault R, et al: 'Chemobrain'in breast carcinoma?: A prologue. Cancer 101:466-475, 2004
51. Ahles TA, Saykin AJ, McDonald BC, et al: Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 110: 143-152, 2008 (Pubitemid 351793851)
52. Ramaiah R, Lam AM: Postoperative cognitive dysfunction in the elderly. Anesthesiol Clin 27:485-496, 2009
53. Bender CM, Sereika SM, Berga SL, et al: Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15:422-430, 2006 (Pubitemid 43826855)
54. Collins B, Mackenzie J, Stewart A, et al: Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 18:134-143, 2009
55. Quesnel C, Savard J, Ivers H: Cognitive impairments associated with breast cancer treatments: Results from a longitudinal study. Breast Cancer Res Treat 116:113-123, 2009
56. Stewart A, Collins B, Mackenzie J, et al: The cognitive effects of adjuvant chemotherapy in early stage breast cancer: A prospective study. Psychooncology 17:122-130, 2008 (Pubitemid 351279862)
57. de Jong-van den Berg LT, Faber A, van den Berg PB: HRT use in 2001 and 2004 in the Netherlands: A world of difference. Maturitas 54:193-197, 2006
58. Castellon S, Ganz PA: Neuropsychological studies in breast cancer: in search of chemobrain. Breast Cancer Res Treat 116:125-127, 2009
59. Correa DD, Ahles TA: Neurocognitive changes in cancer survivors. Cancer J 14:396-400, 2008
60. Jenkins V, Shilling V, Deutsch G, et al: A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828-834, 2006
61. Schagen SB, Vardy J, Steering Committee of the International Cognition and Cancer Task Force: Cognitive dysfunction in people with cancer. Lancet Oncol 8:852-853, 2007
62. Stewart A, Bielajew C, Collins B, et al: A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20:76-89, 2006
63. Vardy J, Rourke S, Tannock IF: Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. J Clin Oncol 25:2455-2463, 2007 (Pubitemid 46999217)
64. Vardy J, Wefel JS, Ahles T, et al: Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Ann Oncol 19:623-629, 2008 (Pubitemid 351461030)
65. Wefel JS, Witgert ME, Meyers CA: Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 18: 121-131, 2008
66. Dugdale AE, Chandler D, Jeffery H: Rapid repeated finger tapping. Aust Paediatr J 16:175-176, 1980 (Pubitemid 11225185)
67. Leslie SC, Davidson RJ, Batey OB: Purdue pegboard performance of disabled and normal readers: unimanual versus bimanual differences. Brain Lang 24:359-369, 1985 (Pubitemid 16215411)
68. Ouimet LA, Stewart A, Collins B, et al: Measuring neuropsychological change following breast cancer treatment: An analysis of statistical models. J Clin Exp Neuropsychol 31:73-89, 2009
69. Schagen SB, Muller MJ, Boogerd W, et al: Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Ann Oncol 13:1387-1397, 2002
70. Schagen SB, van Dam FS, Muller MJ, et al: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650, 1999 (Pubitemid 29075285)
71. Kreukels BP, van Dam FS, Ridderinkhof KR, et al: Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer 8:80-87, 2008 (Pubitemid 351346233)
72. Briones TL, Woods J: Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 12:124, 2011
73. Reiriz AB, Reolon GK, Preissler T, et al: Cancer chemotherapy and cognitive function in rodent models: Memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 12:5000; author reply 5000-5001, 2006
74. Seigers R, Schagen SB, Beerling W, et al: Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 186:168- 175, 2008
75. Seigers R, Schagen SB, Coppens CM, et al: Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res 201:279-284, 2009
76. Winocur G, Vardy J, Binns MA, et al: The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 85:66-75, 2006 (Pubitemid 44802737)
77. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
78. Levine MN, Whelan T: Adjuvant chemotherapy for breast cancer: 30 years later. N Engl J Med 355:1920-1922, 2006 (Pubitemid 44664651)